Funding
← Back to your selection

Safar Partners

Activity from announced rounds

Activity in this selectionOct 17, 2026 · Jul 20, 2026
Rounds participated in
2
Confirmed lead rounds
0
1 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$175M
2 disclosed · full round size, not this investor’s share

By stage

Series A1
Series B1

By primary sector

Biotech1
Hardware1

By country

United States2

Rounds

2 in this selection
Soufflé Therapeutics

Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.

$135MSeries B
Participant
Quintessent

Makes quantum dot laser chips for AI datacenter optical interconnects

$40MSeries A
Role not disclosed